What are the causes of posterior putaminal hyperintensity on imaging studies?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Posterior Putaminal Hyperintensity: Causes

Posterior putaminal hyperintensity on MRI most commonly indicates hypertensive hemorrhage, but can also represent ischemic stroke, manganese deposition in chronic liver disease, or rarely CSF1R-related leukoencephalopathy depending on the clinical context and imaging characteristics.

Primary Causes by Imaging Sequence

T2/FLAIR Hyperintensity

Hypertensive Intracerebral Hemorrhage (Most Common)

  • The putamen is the most frequent site of hypertensive cerebral hemorrhage, presenting with T2 hyperintensity in the acute-to-subacute phase 1
  • Putaminal hemorrhages show a wide range of presentations, from massive hemorrhages extending into white matter and ventricles to small asymptomatic bleeds 1
  • Approximately 45% of spontaneous intracerebral hemorrhages involve the basal ganglia (including putamen) and extend into the ventricular system 2
  • Look for associated findings: mass effect, surrounding edema, and potential intraventricular extension 3

Ischemic Stroke

  • Putaminal infarction presents as T2/FLAIR hyperintensity, typically involving the lenticulostriate artery territory 4
  • May show restricted diffusion on DWI in acute phase (first 7-10 days) 5
  • Associated with poor clinical outcome when involving the corpus striatum (putamen, caudate, pallidum) 4

CSF1R-Related Leukoencephalopathy (Rare)

  • Can show putaminal iron deposition on susceptibility-weighted imaging, though white matter lesions predominate 3
  • Typically presents with frontoparietal white matter lesions as the primary finding, with putaminal changes being secondary 3

T1 Hyperintensity

Chronic Liver Disease/Portosystemic Shunting

  • Bilateral symmetric pallidal (and putaminal) T1 hyperintensity results from manganese accumulation 3
  • Related to portal hypertension and portosystemic shunting rather than hepatic encephalopathy itself 3
  • T2-weighted images remain normal despite T1 hyperintensity 3
  • May increase after TIPS placement and can reverse following liver transplantation or shunt occlusion 3

Subacute Hemorrhage

  • Methemoglobin in subacute hemorrhage (typically 3-21 days post-ictus) causes T1 hyperintensity 5
  • Should have corresponding signal void on T2* GRE or SWI sequences to confirm hemorrhagic etiology 5

Non-Hemorrhagic Ischemic Stroke (Uncommon)

  • T1 hyperintensity can occur in ischemic stroke without hemorrhage, likely due to partial tissue infarction or selective neuronal necrosis 5
  • Appears 1-21 days after onset, either homogeneously throughout the lesion or with rim-like peripheral distribution 5
  • Distinguished from hemorrhage by absence of signal void on GRE/SWI sequences 5

Critical Diagnostic Algorithm

Step 1: Determine the MRI sequence showing hyperintensity

  • T2/FLAIR hyperintensity → Consider hemorrhage (acute-subacute), ischemia, or inflammatory process
  • T1 hyperintensity → Consider chronic liver disease (if bilateral and symmetric), subacute hemorrhage, or non-hemorrhagic infarction

Step 2: Assess for hemorrhage markers

  • Check T2* GRE or SWI sequences for signal void (blooming artifact) 5
  • Signal void present → Confirms hemorrhagic component 5
  • No signal void → Consider non-hemorrhagic ischemia or manganese deposition 3, 5

Step 3: Evaluate distribution pattern

  • Unilateral putaminal involvement → Strongly suggests vascular etiology (hemorrhage or ischemia) 1, 6
  • Bilateral symmetric involvement → Consider manganese deposition from liver disease 3
  • Associated white matter changes → Consider CSF1R-related leukoencephalopathy or small vessel disease 3, 4

Step 4: Correlate with clinical presentation

  • Acute onset with hypertension → Hypertensive hemorrhage most likely 1, 6
  • Liver disease history → Manganese deposition 3
  • Progressive cognitive decline with white matter disease → CSF1R-related disorder 3

Common Pitfalls and Caveats

Do not assume all T1 hyperintensity represents hemorrhage - Non-hemorrhagic ischemic stroke can show T1 hyperintensity without GRE/SWI signal void, particularly in the subacute phase (1-21 days) 5

Timing matters for hemorrhage detection - Most putaminal hemorrhages complete within 6 hours of onset, so early imaging may underestimate final hemorrhage size 6

Bilateral putaminal T1 hyperintensity requires liver function assessment - This finding is highly specific for manganese deposition in chronic liver disease and portosystemic shunting 3

Pontine hyperintensity as a prognostic marker - When posterior putaminal changes are associated with pontine T2 hyperintensity, this combination relates to poor clinical outcome after supratentorial stroke 4

Contrast enhancement is rarely needed - Gadolinium enhancement is not typical for putaminal hemorrhage or ischemia; if present, consider alternative diagnoses such as tumor, infection, or inflammatory conditions 3

References

Research

Putaminal hemorrhages.

Frontiers of neurology and neuroscience, 2012

Guideline

Causes and Diagnosis of Intraventricular Hemorrhage

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.